104347-84-4Relevant academic research and scientific papers
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
, (2017/05/14)
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
, (2015/08/03)
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
NOVEL PYRAZINE DERIVATIVES
-
Paragraph 0325; 0326, (2013/05/09)
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. In particular, the compound may be used as a preferential agonist of Cannabinoid Receptor 2.
NOVEL PYRAZINE DERIVATIVES
-
Page/Page column 45-46, (2013/05/21)
The invention relates to a compound of formula (I), wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
NOVEL PYRIDINE DERIVATIVES
-
Page/Page column 85, (2013/02/27)
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS
-
Page/Page column 173; 174, (2013/02/27)
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
Protease inhibitors
-
, (2008/06/13)
The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.
Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
-
, (2008/06/13)
The present invention relates to compounds and pharmaceutical compositions which inhibit proteases, such as cysteine proteases. In particular, the present invention relates to compounds and pharmaceutical compositions which inhibit cysteine proteases of the papain superfamily. The compounds and pharmaceutical compositions of the present invention are useful for treating diseases, particularly parasitic diseases, which are mediated by such proteases. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.
